Altogen/HUH-7 Transfection Reagent (Liver Cancer Cells)/1.5 ml CRISPR/2158

价格
¥15120.00
货号:2158
浏览量:89
品牌:Altogen
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).


Transfection Reagent for HUH-7 Cells (Liver Cancer Cells)

  • A biodegradable polymer based transfection reagent – once inside the cell, the polymer degrades into smaller less toxic components reducing cell toxicity, facilitating release of the transgene, and improving transfection efficiency
  • Optimized for intracellular delivery of plasmid DNA, siRNA, microRNA, and mRNA
  • High transfection efficiency of both siRNA and plasmid DNA without compromising cell viability
  • Gentle enough to be used for single cell analysis
  • Download in vitro Huh7 transfection protocol: [PDF]
  • Download Huh7 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for Huh7 cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 88% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems Huh-7 Transfection Protocol: [PDF]

Download MSDS: [PDF]

HUH-7 Cell Line:

According to the American Cancer Society, liver cancer has a much better prognosis for complete remission and survival, if diagnosed early. Furthermore, liver cancer caught early has a 50% 5-year survival rate, versus an only 3% survival rate if it is detected late and has spread to other organs. The HuH-7 hepatoma cell line consists of well-differentiated tumorigenic liver cells that are useful for carrying out transfection studies. The HuH-7 cell line was derived from a liver tumor of a 57-year-old Japanese male patient in 1982. HuH-7 is a type of immortal cell line, as hepatoma cells, they exhibit an epithelial cell morphology. In addition to being a suitable transfection host for multiple cellular and molecular biology applications, this cell line is extensively employed in liver cancer research. Common forms of liver cancer are usually caused by viral hepatitis (B or C) infection or cirrhosis. Altogen Biosystems offers polymer-based biodegradable transfection reagents for the HuH-7 hepatoma cell line.

Data:

HUH7 Transfection Reagent

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the Huh-7 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).

HUH7-cells-transfection-protocol

Figure 2. Protein expression of GAPDH in HUH-7 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into HUH-7 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Request a Quote for
HUH-7 Transfection Reagent

Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1775)
  • 1.5 ml (Catalog #1776)
  • 1.5 ml CRISPR (Catalog #2158)
  • 8.0 ml (Catalog #1777)
Altogen生命科学公司致力于研发,生产和销售特定细胞系的转染试剂,用于细胞间生物分子的传递,并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。 Altogen公司开发的聚合物,脂质体,纳米粒子为基础的转染技术分别针对分子生物学,组合化学,和细胞生物学而分别应用。 Altogen定制服务提供符合GLP要求定制研究服务,包括代稳定的细胞系,细胞银行和冷冻保存,焦磷酸测序,克隆,RNA干扰(RNAi)和基因沉默服务,发展分析,siRNA文库筛选,并转染服务。稳定的肿瘤细胞株和原代细胞的产生,可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择,无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务,包括设计与合成的siRNA的利益,验证siRNA的沉默效率,siRNA转染条件的优化,使高效的基因沉默细胞系或原代培养细胞的靶基因。 转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质(即RNA或DNA),通常是在生物实验室用来研究基因功能,基因表达的调节,生化映射,突变分析,和蛋白质的生产。科学家利用各种载体分子,这种分子,使质粒DNA(PDNA),信使RNA(mRNA),短干扰RNA(siRNA),小分子RNA(miRNA)的,并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是,无单提货的方法或转染试剂,可以适用于所有类型的细胞,细胞的细胞毒性和转染效率显着不同,取决于试剂,协议,并正在利用细胞类型。 Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。 纳米粒子,脂质和聚合物基ALTOGEN ®在体内转染试剂,使交付功能的RNA和DNA分子在体内。 PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应,并提供高效的siRNA转染的DNA,并在体内的蛋白质。 由科学“杂志(2010年12月17日):PEG脂质体在体内转染试剂盒siRNA的特色 Altogen生物系统功能的特定细胞系转染试剂盒:   公司:www.altogen.com